901 related articles for article (PubMed ID: 24606022)
21. Can we predict sputum eosinophilia from clinical assessment in patients referred to an adult asthma clinic?
Yap E; Chua WM; Jayaram L; Zeng I; Vandal AC; Garrett J
Intern Med J; 2013 Jan; 43(1):46-52. PubMed ID: 21790924
[TBL] [Abstract][Full Text] [Related]
22. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.
Laviolette M; Gossage DL; Gauvreau G; Leigh R; Olivenstein R; Katial R; Busse WW; Wenzel S; Wu Y; Datta V; Kolbeck R; Molfino NA
J Allergy Clin Immunol; 2013 Nov; 132(5):1086-1096.e5. PubMed ID: 23866823
[TBL] [Abstract][Full Text] [Related]
23. Safety and application of induced sputum analysis in childhood asthma.
Covar RA; Spahn JD; Martin RJ; Silkoff PE; Sundstrom DA; Murphy J; Szefler SJ
J Allergy Clin Immunol; 2004 Sep; 114(3):575-82. PubMed ID: 15356559
[TBL] [Abstract][Full Text] [Related]
24. Mepolizumab and exacerbations of refractory eosinophilic asthma.
Haldar P; Brightling CE; Hargadon B; Gupta S; Monteiro W; Sousa A; Marshall RP; Bradding P; Green RH; Wardlaw AJ; Pavord ID
N Engl J Med; 2009 Mar; 360(10):973-84. PubMed ID: 19264686
[TBL] [Abstract][Full Text] [Related]
25. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
Khatri S; Moore W; Gibson PG; Leigh R; Bourdin A; Maspero J; Barros M; Buhl R; Howarth P; Albers FC; Bradford ES; Gilson M; Price RG; Yancey SW; Ortega H
J Allergy Clin Immunol; 2019 May; 143(5):1742-1751.e7. PubMed ID: 30359681
[TBL] [Abstract][Full Text] [Related]
26. Mepolizumab: First Global Approval.
Keating GM
Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
[TBL] [Abstract][Full Text] [Related]
27. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies.
Goldman M; Hirsch I; Zangrilli JG; Newbold P; Xu X
Curr Med Res Opin; 2017 Sep; 33(9):1605-1613. PubMed ID: 28644104
[TBL] [Abstract][Full Text] [Related]
28. Anti-IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo-controlled, Double-Blind Study.
Sabogal Piñeros YS; Bal SM; van de Pol MA; Dierdorp BS; Dekker T; Dijkhuis A; Brinkman P; van der Sluijs KF; Zwinderman AH; Majoor CJ; Bonta PI; Ravanetti L; Sterk PJ; Lutter R
Am J Respir Crit Care Med; 2019 Feb; 199(4):508-517. PubMed ID: 30192638
[TBL] [Abstract][Full Text] [Related]
29. High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma.
Fowler SJ; Tavernier G; Niven R
J Allergy Clin Immunol; 2015 Mar; 135(3):822-4.e2. PubMed ID: 25445828
[No Abstract] [Full Text] [Related]
30. Mepolizumab and eosinophil-mediated disease.
Walsh GM
Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
[TBL] [Abstract][Full Text] [Related]
31. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma.
Zeiger RS; Schatz M; Li Q; Chen W; Khatry DB; Gossage D; Tran TN
J Allergy Clin Immunol Pract; 2014; 2(6):741-50. PubMed ID: 25439366
[TBL] [Abstract][Full Text] [Related]
32. Morphological changes in eosinophils are reliable markers of the severity of an acute asthma exacerbation in children.
Muniz-Junqueira MI; Barbosa-Marques SM; Junqueira LF
Allergy; 2013 Jul; 68(7):911-20. PubMed ID: 23745834
[TBL] [Abstract][Full Text] [Related]
33. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
[TBL] [Abstract][Full Text] [Related]
34. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.
FitzGerald JM; Bleecker ER; Menzies-Gow A; Zangrilli JG; Hirsch I; Metcalfe P; Newbold P; Goldman M
Lancet Respir Med; 2018 Jan; 6(1):51-64. PubMed ID: 28919200
[TBL] [Abstract][Full Text] [Related]
35. Is a single blood eosinophil count a reliable marker for "eosinophilic asthma?".
Spector SL; Tan RA
J Asthma; 2012 Oct; 49(8):807-10. PubMed ID: 22900679
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab.
Pouliquen IJ; Kornmann O; Barton SV; Price JA; Ortega HG
Int J Clin Pharmacol Ther; 2015 Dec; 53(12):1015-27. PubMed ID: 26445140
[TBL] [Abstract][Full Text] [Related]
37. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
38. Magnitude of late asthmatic response to allergen in relation to baseline and allergen-induced sputum eosinophilia in mild asthmatic patients.
Dente FL; Bacci E; Bartoli ML; Cianchetti S; Di Franco A; Costa F; Vagaggini B; Paggiaro PL
Ann Allergy Asthma Immunol; 2008 May; 100(5):457-62. PubMed ID: 18517078
[TBL] [Abstract][Full Text] [Related]
39. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.
Corren J; Weinstein S; Janka L; Zangrilli J; Garin M
Chest; 2016 Oct; 150(4):799-810. PubMed ID: 27018175
[TBL] [Abstract][Full Text] [Related]
40. A randomized controlled trial on the effect of montelukast on sputum eosinophil cationic protein in children with corticosteroid-dependent asthma.
Strauch E; Moske O; Thoma S; Storm Van's Gravesande K; Ihorst G; Brandis M; Kuehr J
Pediatr Res; 2003 Aug; 54(2):198-203. PubMed ID: 12736396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
